6LS4 image
Entry Detail
PDB ID:
6LS4
Title:
A novel anti-tumor agent S-40 in complex with tubulin
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2020-01-17
Release Date:
2021-01-20
Method Details:
Experimental Method:
Resolution:
2.40 Å
R-Value Free:
0.24
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Tubulin alpha-1B chain
Chain IDs:A, C
Chain Length:451
Number of Molecules:2
Biological Source:Sus scrofa
Polymer Type:polypeptide(L)
Description:Tubulin beta chain
Chain IDs:B, D
Chain Length:445
Number of Molecules:2
Biological Source:Sus scrofa
Polymer Type:polypeptide(L)
Description:Stathmin
Chain IDs:E
Chain Length:152
Number of Molecules:1
Biological Source:Sus scrofa
Primary Citation
A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Cancer Lett. 495 22 32 (2020)
PMID: 32931884 DOI: 10.1016/j.canlet.2020.08.040

Abstact

The tubulin colchicine binding site has been recognized as an attractive drug target to combat cancer, but none of the candidate drugs have been approved for medical treatment. We recently identified a structurally distinct small molecule S-40 as an oral potent tubulin destabilizing agent. Crystal structure analysis of S-40 in a complex with tubulin at a resolution of 2.4 Å indicated that S-40 occupies all 3 zones in the colchicine pocket with interactions different from known microtubule inhibitors, presenting unique effects on assembly and curvature of tubulin dimers. S-40 overcomes paclitaxel resistance and lacks neurotoxicity, which are the main obstacles limiting clinical applications of paclitaxel. Moreover, S-40 harbors the ability to inhibit growth of cancer cell lines as well as patient-derived organoids, induce mitotic arrest and cell apoptosis. Xenograft mouse models of human prostate cancer DU145, non-small cell lung cancer NCI-H1299 and paclitaxel-resistant A549 were strongly restrained without apparent side effects by S-40 oral administration once daily. These findings provide evidence for the development of S-40 as the next generation of orally effective microtubule inhibitors for cancer therapy.

Legend

Protein

Chemical

Disease

Primary Citation of related structures